Tests an SGLT2 drug against placebo in adults with high blood pressure
Tests an SGLT2 drug against placebo in adults with high blood pressure.
Plain-language title generated from the registry record
Registry title: SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
Key facts
- Where
- Porto, PortugalSee the site
- Phase
- Phase 3
Where in Portugal
- University Of PortoPorto, PortugalNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prof. Dr. med. Ingo Eitel
- Trial code
- NCT06804161EU 2025-520794-39-00
- Record updated
- 22 December 2025
- Original description
Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.Read full original descriptionShow less
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.
Inclusion: Age ≥60 years; Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension; A history of at least one CV event (myocardial infarction* or stroke*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; transient ischemic attack); or; The presence of at least one cardiovascular risk factor (current smoking of more than one cigarette per day during at least 1 year; LDL-cholesterol > 4,0 mmol/l, Age ≥ 75 years, ESC HeartScore > 15%, BMI > 32 kg/m2); *excluding patients with myocardial infarction or stroke within preceding 3 months.
Exclusion: Myocardial infarction or stroke within the previous 3 months; Receiving therapy with an SGLT2i within 8 weeks prior to randomization or previous intolerance to an SGLT2i; Participation in another clinical study with an investigational product during the last month prior to enrolment; Symptomatic heart failure (including HFrEF, HFmEF, HFpEF); History of Diabetes mellitus; History of ketoacidosis; Known allergy or hypersensitivity to SGLT2i; Any medical condition - outside the renal and CV disease area - with a life expectancy of less than 2 years based on investigator's clinical judgement; Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma); Hepatic impairment (aspartate transaminase [AST] or alanine transaminase [ALT] >3x the upper limit of normal [ULN]); eGFR <25 mL/min/1.73 m2 (CKD-EPICr 2021 formula) at Visit 1; Women who are pregnant, nursing, or who plan to become pregnant while in the trial; Inability to give informed consent.